Zealand Pharma A/S/ADR
ZLDPFDrugs in Pipeline
5
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
dasiglucagon
Congenital Hyperinsulinism
Glepaglutide
Short Bowel Syndrome
GlucaGen
Hypoglycemia
Thiotepa
Acute Lymphoblastic Leukaemia
Petrelintide
Overweight
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
dasiglucagon | Phase 3 | Congenital Hyperinsulinism | - | - |
Glepaglutide | Phase 3 | Short Bowel Syndrome | - | - |
GlucaGen | Phase 3 | Hypoglycemia | - | - |
Thiotepa | Phase 3 | Acute Lymphoblastic Leukaemia | - | - |
Petrelintide | Phase 2 | Overweight | - | - |
Frequently asked questions
What is in Zealand Pharma A/S/ADR's drug pipeline?→
CatalystAlert tracks 5 drug candidates in Zealand Pharma A/S/ADR's (ZLDPF) pipeline across Phase 3, Phase 2. Its lead program is dasiglucagon (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Zealand Pharma A/S/ADR's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Zealand Pharma A/S/ADR (ZLDPF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ZLDPF biotech catalysts?→
Add ZLDPF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Zealand Pharma A/S/ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.